Lionsbridge Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Lionsbridge Wealth Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,607	Closed	-$1.47M	–	54
2021 Q4	$1.47M	Sell	9,607 -123	-1%	-$19K	1.57%	30
2021 Q3	$1.57M	Sell	9,730 -207	-2%	-$34.8K	1.7%	18
2021 Q2	$1.63M	Buy	9,937 +2,677	+37%	+$412K	1.74%	16
2021 Q1	$1.09M	Buy	7,260 +346	+5%	+$55K	1.07%	44
2020 Q4	$1.05M	Buy	6,914 +348	+5%	+$49.7K	1.13%	40
2020 Q3	$889K	Buy	6,566 +1,103	+20%	+$150K	1.07%	38
2020 Q2	$746K	Buy	+5,463	New	+$696K	0.84%	38
2020 Q1	–	Sell	-91	Closed	-$10K	–	158
2019 Q4	$10K	Buy	+91	New	+$10.2K	0.01%	118

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lionsbridge Wealth Management's IBB Position: Q1 2022 in Review

Lionsbridge Wealth Management sold out of iShares Biotechnology ETF (IBB) in Q1 2022, closing a stake of 9,607 shares — an estimated $1.47M sold.

Lionsbridge Wealth Management first reported a position in IBB in Q4 2019 and held it in 8 quarters. The position peaked at $1.63M in Q2 2021. 898 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

Lionsbridge Wealth Management reported no remaining iShares Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
Lionsbridge Wealth Management sold 9,607 iShares Biotechnology ETF shares in Q1 2022, an estimated $1.47M.
Lionsbridge Wealth Management first reported a position in iShares Biotechnology ETF in Q4 2019 and held it in 8 quarters.
Lionsbridge Wealth Management's iShares Biotechnology ETF position peaked at $1.63M in Q2 2021.
898 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on Lionsbridge Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.